Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Arrhythmogenic Right Ventricular Dysplasia
Interventions
DRUG

Spironolactone

The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.

DRUG

Placebo

Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.

Trial Locations (13)

Unknown

NOT_YET_RECRUITING

CHU Amiens Picardie, Amiens

RECRUITING

Hôpital Cardiologique Louis Pradel, Bron

NOT_YET_RECRUITING

Hôpital Gabriel Montpied, Clermont-Ferrand

NOT_YET_RECRUITING

CHU Dijon, Dijon

NOT_YET_RECRUITING

Hôpital Michallon, Grenoble

NOT_YET_RECRUITING

Hôpital de la Timone, Marseille

NOT_YET_RECRUITING

Hôpital Arnaud de Villeneuve, Montpellier

NOT_YET_RECRUITING

Hôpital Laennec, Nantes

NOT_YET_RECRUITING

Groupe Hospitalo Universitaire Caremeau, Nîmes

NOT_YET_RECRUITING

Hôpital Pitié Salpetrière, Paris

NOT_YET_RECRUITING

Hôpital de Haut-Lévêque, Pessac

NOT_YET_RECRUITING

Nouvel Hôpital Civil, Strasbourg

NOT_YET_RECRUITING

Hôpital Rangueil, Toulouse

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER